Dr. Tanguy Seiwert explores the emerging role for immunotherapy in head and neck cancer.
This activity is intended for oncologists, surgeons, and pathologists.
The goal of this activity is to discuss advances in the understanding of the role of the immune system in the head and neck cancer and strategies for using the immune system to treat head and neck cancer.
Approximate Time to Complete: 40 minutes
Course Available Beginning: Nov. 15, 2016
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the mechanisms of action of emerging immunotherapeutic agents and their implications for clinical practice in patients with recurrent or metastatic head and neck cancer
- Have increased knowledge regarding the potential impact of human papillomavirus (HPV), programmed cell death ligand 1 (PD-L1) status, and expression profiling (ie, interferon- γ [IFN-γ] signature) on a patient's clinical response to immune checkpoint inhibitors
- Have greater competence related to identifying appropriate candidates for emerging cancer immunotherapies for recurrent or metastatic head and neck cancer